Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001085602 | SCV000632592 | likely benign | Carnitine palmitoyltransferase II deficiency | 2024-01-29 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000757136 | SCV000885260 | likely benign | not provided | 2018-03-17 | criteria provided, single submitter | clinical testing | The c.1602G>A; p.Glu534Glu variant (rs148110518, ClinVar variant ID 460425) does not alter the amino acid sequence of the CPT2 protein and computational splice site prediction algorithms do not predict a change in the nearest splice site or creation of a cryptic splice site. This variant has not been reported in medical literature or in gene specific variation databases. This variant is listed in the genome Aggregation Database (gnomAD) with a Latino population frequency of 0.1% (identified on 37 out of 33,984 chromosomes). Based on the available information, the c.1602G>A variant is likely to be benign. |
Ce |
RCV000757136 | SCV001147287 | uncertain significance | not provided | 2016-06-01 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003942769 | SCV004759285 | likely benign | CPT2-related disorder | 2019-10-28 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Genome Diagnostics Laboratory, |
RCV000757136 | SCV001928673 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000757136 | SCV001968627 | likely benign | not provided | no assertion criteria provided | clinical testing |